Misplaced Pages

2-Oxazolidone

Names
Preferred IUPAC name 1,3-Oxazolidin-2-one
Other names 1,3-Oxazolidin-2-one, 2-Oxo-1,3-oxazolidine, 2-Oxotetrahydro-1,3-oxazole
Identifiers
CAS Number	497-25-6
3D model (JSmol)	Interactive image
ChemSpider	66579
ECHA InfoCard	100.007.129
KEGG	C06695
PubChem CID	73949
UNII	Z4D49W92PP
CompTox Dashboard (EPA)	DTXSID2074326
InChI InChI=1S/C3H5NO2/c5-3-4-1-2-6-3/h1-2H2,(H,4,5)Key: IZXIZTKNFFYFOF-UHFFFAOYSA-N InChI=1/C3H5NO2/c5-3-4-1-2-6-3/h1-2H2,(H,4,5)Key: IZXIZTKNFFYFOF-UHFFFAOYAE
SMILES O=C1OCCN1
Properties
Chemical formula	C3H5NO2
Molar mass	87.077 g/mol
Appearance	white or colorless solid
Melting point	86 to 89 °C (187 to 192 °F; 359 to 362 K)
Boiling point	220 °C (428 °F; 493 K) at 48 torr
Related compounds
Related compounds	Oxazolidine
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Y verify (what is  ?) Infobox references

2-Oxazolidinone is a heterocyclic organic compound containing both nitrogen and oxygen in a 5-membered ring.

Synthesis and occurence

The compound arises by the reaction of an ethanolamine and dimethylcarbonate or related phosgene equivalents.

It is one of waste products generated in amine gas treating due to cyclization of ethanolamine carbamate.

History

The compound was first reported in 1888 by German chemist Siegmund Gabriel. While investigating reactions of bromoethylamine hydrobromide, he treated it with silver carbonate and isolated a product with melting point around 90–91°C. He determined its empirical formula correctly, but neither gave it a specific name not studied its properties.

Nine years later Gabriel returned to the topic together with G. Eschenbach, developing a more efficient synthesis using sodium bicarbonate instead of the silver salt. They referred to the compound as "Oxäthylcarbaminsäureanhydrid" (hydroxyethylcarbamic acid anhydride), recognizing its relationship to ethanolamine and its cyclic structure. Their 1897 paper focused on optimizing the yield of oxazolidone and investigating some of its reactions, such as its conversion to 1-(2-hydroxyethyl)-3-phenylurea upon treatment with aniline.

Substituted oxazolidinones

Evans auxiliaries

Oxazolidinones are useful as Evans auxiliaries, which are of interest for chiral synthesis. In a common implementation, an acid chloride substrate reacts with a chiral oxazolidinone to form an imide. Substituents at the 4 and 5 position of the oxazolidinone direct any aldol reaction to the alpha position of the carbonyl of the substrate. Asymmetric Diels-Alder reactions are also enabled by these auxiliaries.

Pharmaceuticals

Oxazolidinones are found in some antimicrobials. Oxazolidinones inhibit protein synthesis by interfering with the binding of N-formylmethionyl-tRNA to the ribosome. (See Linezolid#Pharmacodynamics)

Some of the most important oxazolidinones are antibiotics.

Examples of oxazolidinone-containing antibiotics:

• Linezolid (Zyvox), which is available for intravenous administration and also has the advantage of having excellent oral bioavailability.
• Posizolid, which appears to have excellent, targeted bactericidal activity against all common gram-positive bacteria, regardless of resistance to other classes of antibiotics.

• Tedizolid, (Sivextro) which is approved for acute skin infections
• Radezolid (RX-1741) has completed some phase-II clinical trials.
• Contezolid (MRX-I) has reported phase 1 data and phase III data. In 2021, a new drug summary was published by ADIS Press. In June 2021, marketing approval was granted by the Chinese National Medical Products Administration (NMPA) for use of oral contezolid in moderate to severe complicated skin and skin structure infections. In June 2022, contezolid oral tablets and contezolid acefosamil IV (a prodrug of contezolid) began Phase 3 global clinical trials in moderate to severe diabetic foot infections. An additional global Phase 3 study is planned for acute bacterial skin and skin structure infections (ABSSSI) for the combination of contezolid and contezolid acefosamil.
• An oxazolidinone derivative used for other purposes is rivaroxaban, which is approved by the U.S. FDA for venous thromboembolism prophylaxis.

A first commercially available 1,3-oxazolidinone is the antibiotic linezolid.

See also

• Oxazolidine – the ring without the carbonyl group
• Oxazolone – the unsaturated analogues

References

1. Karl-Heinz Scholz, Hans-Georg Heine, Willy Hartmann (1984). "Synthesis and Diels–Alder Rearctions of 3-Acetyl-2(3H)-Oxazolone: 6-Amino-3,4-dimethyl-cis-3-cyclohexen-1-ol". Organic Syntheses. 62: 149. doi:10.15227/orgsyn.062.0149.{{cite journal}}: CS1 maint: multiple names: authors list (link)
2. T. Akiba, O. Tamura, S. Terashima (1998). "(4R,5S)-4,5-Diphenyl-3-Vinyl-2-Oxazolidinone". Organic Syntheses. 75: 45. doi:10.15227/orgsyn.075.0045.{{cite journal}}: CS1 maint: multiple names: authors list (link)
3. Salim, S. R. S. (2021-03-01). "Treatment of amine wastes generated in industrial processes". IOP Conference Series: Materials Science and Engineering. 1092 (1): 012051. doi:10.1088/1757-899x/1092/1/012051. ISSN 1757-8981.
4. Gabriel, S. (1888). "Ueber einige Derivate des Aethylamins". Berichte der Deutschen Chemischen Gesellschaft (in German). 21 (1): 566–575. doi:10.1002/cber.188802101103. ISSN 0365-9496.
5. Gabriel, S.; Eschenbach, G. (September 1897). "Notizen über Bromäthylamin und Vinylamin". Berichte der Deutschen Chemischen Gesellschaft (in German). 30 (3): 2494–2497. doi:10.1002/cber.18970300324. ISSN 0365-9496.
6. James R. Gage, David A. Evans (1990). "Diastereoselective Aldol Condensation Using a Chiral Oxazolidinone Auxiliary: (2S,3S)-3-Hydroxy-3-Phenyl-2-Methylpropanoic Acid". Organic Syntheses. 68: 83. doi:10.15227/orgsyn.068.0083.
7. S. Pikul, E. J. Corey (1993). "Enantioselective, Catlytic Diels-Alder Reaction: (1S-endo)-3-(Bicyclo[2.2.1]Hept-5-en-2-ylcarbonyl)-2-Oxazolidinone". Organic Syntheses. 71: 30. doi:10.15227/orgsyn.071.0030.
8. Shinabarger, D. (1999). "Mechanism of action of the oxazolidinone antibacterial agents". Expert Opinion on Investigational Drugs. 8 (8): 1195–1202. doi:10.1517/13543784.8.8.1195. PMID 15992144.
9. Sonia Ilaria Maffioli (2014). "A Chemist's Survey of Different Antibiotic Classes". In Claudio O. Gualerzi; Letizia Brandi; Attilio Fabbretti; Cynthia L. Pon (eds.). Antibiotics: Targets, Mechanisms and Resistance. Wiley-VCH. ISBN 9783527659685.
10. Wookey, A.; Turner, P. J.; Greenhalgh, J. M.; Eastwood, M.; Clarke, J.; Sefton, C. (2004). "AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro". Clinical Microbiology and Infection. 10 (3): 247–254. doi:10.1111/j.1198-743X.2004.00770.x. PMID 15008947.
11. "Rx 1741". Rib-X Pharmaceuticals. 2009. Archived from the original on 2009-02-26. Retrieved 2009-05-17.
12. Gordeev, Mikhail F.; Yuan, Zhengyu Y. (2014). "New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile". Journal of Medicinal Chemistry. 57 (11): 4487–4497. doi:10.1021/jm401931e. PMID 24694071.
13. Zhao, Xu; Huang, Haihui; Yuan, Hong; Yuan, Zhengyu; Zhang, Yingyuan (2022). "A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections". Journal of Antimicrobial Chemotherapy. 77 (6): 1762–1769. doi:10.1093/jac/dkac073. PMID 35265985.
14. Hoy, Sheridan M. (2021). "Contezolid: First Approval". Drugs. 81 (13): 1587–1591. doi:10.1007/s40265-021-01576-0. PMC 8536612. PMID 34365606.
15. "China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection – MicuRx Pharmaceuticals, Inc".
16. ClinicalTrials.gov Identifier: NCT05369052

External links

• Synthesis of Oxazolidinones – Recent Literature

• Oxazolidinones
• 2-Oxazolidinones